All Data
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
Dr Reddy's recently received permission from DCGI to conduct phase II and III trials of the Russian vaccine. If it receives an approval to continue, it will recruit 1,400 subjects for phase III.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GPP-Baladol
Therapeutic Area: Infections and Infectious Diseases Product Name: PNB-001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
The company, which has its labs in England, had in early September 2020 received approval from the Drug Controller General (DCGI) to conduct the phase 2 clinical trial of GPP-Baladol in patients with moderate infection of the pandemic with oxygen support.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GPP-Baladol
Therapeutic Area: Infections and Infectious Diseases Product Name: PNB-001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2021
Details:
The company had received approval from the Drug Controller General of India (DCGI) to conduct the Phase 2 Clinical trial of GPP-BALADOL in COVID-19 moderate patients with oxygen support in September 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon Alfa-2B
Therapeutic Area: Infections and Infectious Diseases Product Name: PegiHep
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
In a regulatory filing, Zydus Cadila has received approval from the DCGI to start the phase 3 clinical trials in COVID-19 patients with its biological therapy Pegylated Interferon alpha-2b or PegiHep.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pegylated Interferon alpha-2b
Therapeutic Area: Infections and Infectious Diseases Product Name: PegiHep
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
Pegylated Interferon alpha – 2b significantly increased viral reduction and reduced the need for supplemental oxygen in moderate COVID-19 patients; the Company will now commence Phase III clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GPP-Baladol
Therapeutic Area: Infections and Infectious Diseases Product Name: PNB-001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
The effect of PNB 001 (GPP-Baladol) will be compared with dexamethasone, currently the most used medication for COVID-19 treatment. The molecule has already been patented and the related IPRs have been secured by PNB VESPER in the US, Europe and rest of the world.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BBV152
Therapeutic Area: Infections and Infectious Diseases Product Name: Covaxin
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2020
Details:
The latest development is supported by assessment of safety and immunogenicity data of Phase I and II clinical trials of Covaxin. Covaxin has been derived from a strain of SARS-CoV-2 virus and uses adjuvant Alhydroxiquim-II to boost immune response.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
